2. Levine M., Nikkanen H., Pallin D.J. The effects of intravenous calcium in patients with digoxin toxicity. J. Emerg. Med. 2011;40:41–46.

3. Ho K. A critically swift response: insulin-stimulated potassium and glucose transport in skeletal muscle. Clin. J. Am. Soc. Nephrol. 2011;6:1513–1516.

4. DeFronzo R.A., Felig P., Ferrannini E., Wahren J. Effect of graded doses of insulin on splanchnic and peripheral potassium metabolism in man. Am. J. Physiol. 1980;238:E421–427.

5. Nguyen T.Q., Maalouf N.M., Sakhaee K., Moe O.W. Comparison of insulin action on glucose versus potassium uptake in humans. Clin. J. Am. Soc. Nephrol. 2011;6:1533–1539.

6. Elliott M.J., Ronksley P.E., Clase C.M., Ahmed S.B., Hemmelgarn B.R. Management of patients with acute hyperkalemia. CMAJ. 2010; 182:1631–1635.

7. Allon M., Dunlay R., Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann. Intern. Med. 1989;110:426–429.

8. Palmer B.F. Regulation of potassium homeostasis. Clin. J. Am. Soc. Nephrol. 2015;10:1050–1060.

9. Iqbal Z., Friedman E.A. Preferred therapy of hyperkalemia in renal insufficiency: survey of nephrology training-program directors. N. Engl. J. Med. 1989;320:60–61.

10. Gutierrez R., Schlessinger F., Oster J.R., Rietberg B., Perez G.O. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab. 1991;17:297–302.

11. Greenberg A. Hyperkalemia: treatment options. Semin. Nephrol. 1998;18:46– 57.

12. Kao K.C., Huang C.C., Tsai Y.H., Lin M.C., Tsao T.C. Hyperkalemic cardiac arrest successfully reversed by hemodialysis during cardiopulmonary resuscitation: case report. Chang Gung Med. J. 2000;23:555–559.

13. Blumberg A., Roser H.W., Zehnder C., Muller-Brand J. Plasma potassium) in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrol. Dial. Transplant. 1997;12:1629–1634.

14. Sherman R.A., Mehta O.: Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin. J. Am. Soc. Nephrol. 2009;4(8):1370–1373.

15. Sterns R.H., Rojas M., Bernstein P., Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? Jam. Soc. Nephrol. 2010;21:733–735.

16. Harel Z., Harel S., Shah P.S., Wald R., Perl J., Bell C.M. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am. J. Med. 2013;126:264.e9-264.e24.

17. US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate) powder: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) – September 2009. Available at http://www.fda.gov/ Safety/MedWatch/Safetyinformation/ucm186845.htm. Accessed September 15;2015

18. Watson M.A., Baker T.P., Nguyen A., Sebastianelli M.E., Stewart H.L., Oliver D.K., Abbott K.C., Yuan C.M. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am. J. Kidney. Dis. 2012; 60:409–416.

19. Ziessman H. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. Southern. Med. J. 1976;69:497–499.

20. Hirasawa Y. Clinical experience in using Kalimate in patients with renal failure. Medical consultations & new remedies. 1973;10:1021–1029.

21. Suzuki Y., Mimura N. Inhibitory effects of calcium polystyrene sulphonate (Kalimate) on serum potassium values in cases of hyperkalemia accompanying renal failure. Clinical medicine. 1973;15(12):1794–1806.

22. Information of adverse drug reaction № 40. Safety Division, Pharmaceutical affairs bureau, Ministry of Health and Welfare. Japan. Dec. 1979.

23. Minford E.J., Hand T., Jones M.C. Constipation and colonic perforation complicating calcium resonium therapy (Letter to the editor). Postgrad Med J.1992;68(798):302.

24. Li Xiao, Xu Gang, Lin Hong-li, Hu Zhao, Yu Xue-qing, Xing Chang-ying, Mei Chang-lin, Zuo Li, Ni Zhao-hui, Ding Xiao-qiang, Li De-tian, Chen Nan. Calcium Polystyrene Sulfonate in Treating Hyperkalemia Patients with Chronic Kidney Disease: Multi-center Clinical Study. Chin. J. Nephrol. 2013;29(6):419–422.

25. Ватазин А.В., Шилов Е.М., Хозяинова Н.Ю. Новые возможности коррекции гиперкалимии у пациентов с хронической болезнью почек. Нефрология. 2016;20:47–53.

26. Tomino Y.1, Yamazaki T., Shou I., Tsuge T., Satake K., Takeda Y., Ohtani A., Nishitani T., Kurusu A., Hamada C., Horikoshi S., Maeda K., Tanaka Y., Fukuda H., Wakabayashi M., Seto T. Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia-changes in serum potassium levels with or without a RAAS inhibitor. Clin. Nephrol. 2007;68(6):379–385.

27. Yu M.Y., Yeo J.H., Park J.S. Lee C.H., Kim G.H. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS One. 2017. Mar. 22;12(3):e0173542.

28. Einhorn L.M., Zhan M., Hsu V.D., Walker L.D., Moen M.F., Seliger S.L., Weir M.R., Fink J.C. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 2009;169:1156–1162.

Поступила 15.06.2017

Принята в печать 05.09.2017

Received 15.06.2017

Accepted 05.09.2017